The present invention is directed to novel B7-H3 binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that cross-react with non-human primate (eg cynomolgus monkey) B7-H3. The invention further provides a B7- comprising a variable light chain and / or variable heavy chain (VH) domain humanized and / or de-immunized to exhibit reduced immunogenicity upon administration to a recipient subject. Relates to H3-binding molecules. The invention particularly relates to: a bispecific diabody, BiTE, bispecific comprising (i) the above B7-H3 binding variable domain； and (ii) a domain capable of binding to an epitope of a molecule present on the surface of effector cells. Bispecific, trispecific or multispecific B7-H3 binding molecules, including sex antibodies, trivalent binding molecules and the like. The present invention is also directed to pharmaceutical compositions containing any of the above B7-H3 binding molecules and methods involving the use of any of the above B7-H3 binding molecules in the treatment of cancer and other diseases and conditions. The invention also relates to a molecule comprising a human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety ("B7-H3-ADC"). The present invention is also directed to pharmaceutical compositions containing the B7-H3-ADC as described above, and methods involving the use of any of the B7-H3-ADCs as described above in the treatment of cancer and other diseases and conditions.本発明は、ヒト及び非ヒトＢ７‐Ｈ３に結合できる新規のＢ７‐Ｈ３結合分子、並びに特に非ヒト霊長類（例えばカニクイザル）のＢ７‐Ｈ３と交差反応する上記分子を対象とする。本発明は更に、レシピエントである被験者への投与時に免疫原性の低減を示すようヒト化及び／又は脱免疫化された可変軽鎖及び／又は可変重鎖（ＶＨ）ドメインを含む、Ｂ７‐Ｈ３結合分子に関する。本発明は特に：（ｉ）上記Ｂ７‐Ｈ３結合可変ドメイン；及び（ｉｉ）エフェクタ細胞の表面上に存在する分子のエピトープに結合できるドメインを含む、二重特異性ダイアボディ、ＢｉＴＥ、二重特異性抗体、３価結合分子等を含む二重特異性、三重特異性又は多重特異性Ｂ７‐Ｈ３結合分子に関する。本発明はまた、上記Ｂ７‐Ｈ３結合分子のいずれを含有する医薬組成物、並びに癌並びに他の疾患及び状態の治療における上記Ｂ７‐Ｈ３結合分子のいずれの使用を伴う方法も対象とする。本発明はまた、少なくとも１つの薬物部分にコンジュゲートしたヒト化抗ヒトＢ７‐Ｈ３抗体のヒトＢ７‐Ｈ３結合ドメインを含む分子（「Ｂ７‐Ｈ３
